Fresenius Kabi Oncology Limited operates in the Pharmaceutical preparations sector. Fresenius Kabi Oncology Ltd. is a provider of cancer research and anti-cancer products. The Company provides third-generation chemotherapeutic drugs from developing to manufacturing and marketing worldwide. It is engaged in development and manufacturing of active pharmaceutical ingredients (APIs), intermediates and oral and injectable finished dosage forms. The Company's finished dosage forms are manufactured at its manufacturing units in Himachal Pradesh (India). Its active pharmaceutical ingredients are manufactured at West Bengal (India). Its product portfolio consists of 40 formulations, including cytotoxic and cytostatic in both I.V. and oral dosage forms. During the fiscal year ended March 31, 2011 (fiscal 2011), it had a production of 51,171 liters of injection and 19,755 kilograms of bulk drugs. Effective January 14, 2011, the Company dissolved its wholly owned subsidiary, Dabur Pharma (Thailand) Co. Ltd. In their complete report available for purchase the company is compared to: Merck Limited, Ajanta Pharma Limited and Sharon Bio-Medicine Ltd.
Fresenius Kabi Oncology Limited Live Stock Prices, Quotes, Tips & News
Fresenius Kabi Oncology Limited operates in the Pharmaceutical preparations sector. Fresenius Kabi Oncology Ltd. is a provider of cancer research and anti-cancer products. The Company provides third-generation chemotherapeutic drugs from developing to manufacturing and marketing worldwide. It is engaged in development and manufacturing of active pharmaceutical ingredients (APIs), intermediates and oral and injectable finished dosage forms. The Company's finished dosage forms are manufactured at its manufacturing units in Himachal Pradesh (India). Its active pharmaceutical ingredients are manufactured at West Bengal (India). Its product portfolio consists of 40 formulations, including cytotoxic and cytostatic in both I.V. and oral dosage forms. During the fiscal year ended March 31, 2011 (fiscal 2011), it had a production of 51,171 liters of injection and 19,755 kilograms of bulk drugs. Effective January 14, 2011, the Company dissolved its wholly owned subsidiary, Dabur Pharma (Thailand) Co. Ltd. In their complete report available for purchase the company is compared to: Merck Limited, Ajanta Pharma Limited and Sharon Bio-Medicine Ltd.
